• Skip to primary navigation
  • Skip to main content
  • Skip to footer

HepVu

HepVu

An estimated 3.5 million people in the U.S. are living with chronic Hepatitis C infection.

  • View the Map
  • Local Data
  • Find Services
  • News & Updates
  • Events
  • Tools & Resources
Home Local Data New Jersey

Local Data: New Jersey

There are approximately 47,200 people living with Hepatitis C in New Jersey.

New Jersey

Want to view more?

View Interactive Map

Jump to:

  • Prevalence
  • Mortality
  • Demographics
  • Age
  • Other Data Comparisons

Hepatitis C Prevalence

Estimated number of people living with Hepatitis C, 2013-2016 47,200

Estimated rate of people living with Hepatitis C per 100,000 population, 2013-2016 680

Estimated percent of people living with Hepatitis C, by Sex, 2013-2016

69.6% 30.4%
  • Male
  • Female

Estimated percent of people living with Hepatitis C, by Race/Ethnicity, 2013-2016

31.0% 69.0%
  • Black
  • Non-Black

Estimated percent of people living with Hepatitis C, by Age, 2013-2016

3.7% 66.7% 29.6%
  • Less than 50
  • 50-74 (Baby Boomer)
  • 75 and above

Estimated rate of people living with Hepatitis C per 100,000 population, by Geography, 2013-2016

1000 800 600 400 200 0 680.0 State 776.6 Region 926.5 United States

Hepatitis C Mortality

Number of deaths related to Hepatitis C, 2017 342

Rate of deaths related to Hepatitis C per 100,000 population, 2017 4

Percent of deaths of people related to Hepatitis C, by Sex, 2017

69.0% 31.0%
  • Male
  • Female

Percent of deaths of people related to Hepatitis C, by Race/Ethnicity, 2017

16.1% 29.8% 52.6% 1.5%
  • American Indian or Alaska Native, Asian or Pacific Islander, or Hispanic/Latinx
  • Black
  • White
  • Data suppressed or not available

Percent of deaths of people related to Hepatitis C, by Age, 2017

2.9% 81.9% 8.2% 7.0%
  • Less than 50
  • 50-74 (Baby Boomer)
  • 75 and above
  • Data suppressed or not available

Number of deaths related to Hepatitis C, 2013-2017

2013 2014 2015 2016 2017 300 400 500 424 446 400 378 342

Rate of deaths related to Hepatitis C per 100,000 population, by Geography, 2017

10 8 6 4 2 0 4.0 State 3.9 Region 5.3 United States

Demographics, 2017

Total Population 9,005,644

State Population By Age

  • Less than 50 (63.5%)
  • 50-74 (Baby Boomer) (29.7%)
  • 75 and above (6.8%)

Hepatitis C, by Age

Estimated Percent of People Living with Hepatitis C, by Age, 2013-2016

Percent of Deaths Related to Hepatitis C, by Age, 2017

  • Less than 50
  • 50-74 (Baby Boomer)
  • 75 and above
  • Data suppressed or not available

Opioid Indicators

Opioid Prescription Rate, 2020 31.8

Pain Reliever Misuse Percent, 2019-2020 3.2

Narcotic Overdose Mortality Rate, 2020 32.1

Social Determinants of Health, 2018

  • State
  • Region
  • United States
89.3% 88.8% 87.5%

Percent of Population with a High School Education, 2018

0.481 0.492 0.481

Income Inequality (Gini Coefficient), 2018

10.4% 12.5% 14.0%

Percent of Population Living in Poverty, 2018

$76,212 $64,974 $59,039

Median Household Income, 2018

9.2% 6.8% 8.6%

Percent of Population Lacking Health Insurance, 2018

Viral Hepatitis Treatment Restrictions

Fibrosis Level Treatment Restrictions

State Medicaid programs may require a patient to reach a certain stage of fibrosis (liver scarring) before being able to access treatment for Hepatitis C.

F4 F3 F2 F1 No Restrictions

Sobriety Treatment Restrictions

State Medicaid programs may require patients to be sober for a specified amount of time before being able to access treatment for Hepatitis C.

6 months 3 months 1 month Screening and Counseling No Restrictions

Prescriber Treatment Restrictions

State Medicaid programs may require patients to see a specific type of specialist in order to receive treatment for Hepatitis C.

Specialist By or In Consultation No Restrictions

Prior Authorization

State Medicaid programs may require patients to receive prior authorization in order to receive treatment for Hepatitis C.

Prior Authorization Required Prior Authorization Removed

Status of state Medicaid treatment restrictions is as of January 2022. Source: CHLPI & NVHR.

Sign up for HepVu updates.

Footer

AIDSVu HepVu

HepVu is presented by Emory University’s Rollins School of Public Health in partnership with Gilead Sciences, Inc.

  • About
  • FAQ
  • Data Methods
  • Datasets

Questions?
Info@HepVu.org

Media Inquiries
(202) 854-0480
Media@HepVu.org

Follow Us

  • Facebook
  • Twitter

© 2022 HepVu. All Rights Reserved.

  • Privacy Policy
  • Contact Us

Get HepVu in Your Inbox

Sign up to stay informed on new data, maps, expert Q&As, and infographics about Hepatitis C and opioids where you live.